8622 (8622) Fair Value & Analysis

Healthcare · Market cap HK$103M

8 8622 8622 · HK

PriceHK$0.2000

Fair ValueHK$0.0800

Upside-60.0%

Quality36/100

Watch 8622 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.0500 – HK$0.1000

Fair value as of: Jul 3, 2026

From 1 valuation models · updated today

Share price −9.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1940 – HK$0.7000 · fair‑value band HK$0.0500 – HK$0.1000 · the HK$0.2000 price screens above the HK$0.0800 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8622 (8622) currently trades at HK$0.2000, while our model-based Fair Value estimate is HK$0.0800 — implying the stock looks roughly 60.0% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 8622 generated revenue of HK$28.3M at a net margin of -17.7%. Revenue grew 18.7% year over year. It earns a return on equity of -9.5%. The balance sheet holds a net cash position of HK$32.0M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$28.3M

Revenue growth (YoY) +18.7%

Net margin -17.7%

Return on equity -9.5%

Free cash flow −HK$3.3M FY2025

Operating margin -34.5%

More key figures

EPS growth (YoY) -41.4%

Net cash HK$32.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8622 reported revenue of HK$28.3M in FY2025 versus HK$26.1M in FY2021, a compound +2.0%/yr. Reported net income was −HK$5.0M in FY2025.

Revenue +2.0%/yr

FY21 HK$26.1M

FY22 HK$25.3M

FY23 HK$24.6M

FY24 HK$25.4M

FY25 HK$28.3M

Net income

FY21 −HK$4.2M

FY22 −HK$3.1M

FY23 −HK$5.8M

FY24 −HK$4.2M

FY25 −HK$5.0M

Is 8622 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8622 (8622) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$0.0800 versus a price of HK$0.2000 — about −60% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 8622?

Our model-based fair value for 8622 is HK$0.0800 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.2000.

What is the quality score of 8622?

8622 has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8622 (8622)?

8622 reported trailing-twelve-month revenue of about HK$28.3M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 8622?

The net profit margin of 8622 is about -17.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.